Health System Reimbursement
The resources below can help support health systems and hospitals to understand the reimbursement pathways for DefenCath.
Leverage resources below to help your health system integrate DefenCath seamlessly, from formulary inclusion to product ordering.
DefenCath Prescribing Information
Download the Prescribing Information for DefenCath (taurolidine and heparin) catheter lock solution.
Introduction to NTAP
Download this resource for NTAP billing and coding information.
NTAP Billing Guide
Download this resource for NTAP billing and coding information for inpatient use of DefenCath (taurolidine and heparin).
TDAPA Billing Guide
Download this guide for TDAPA billing information for DefenCath (taurolidine and heparin) catheter lock solution.
Pass-Through Payment Billing Guide
Download this guide to learn about the Pass-Through status granted to DefenCath (taurolidine and heparin).
DefenCath Product Ordering Sheet
Download this resource to help navigate the product ordering process.
Schedule an Appointment
Visit DefencathSupport.com to schedule an appointment with a reimbursement specialist.
CRBSI = catheter-related bloodstream infection; NTAP = New Technology Add-on Payment; TDAPA = Transitional Drug Add-on Payment Adjustment.
Reference: 1. DefenCath (taurolidine and heparin) [prescribing information]. Berkeley Heights, NJ: CorMedix Inc; 2023.
Speak with a representative
Have questions about DefenCath? Open the form below to request a call with a representative.
Open formIMPORTANT SAFETY INFORMATION (cont'd)
CONTRAINDICATIONS
DefenCath is contraindicated in patients with:
- Known heparin-induced thrombocytopenia (HIT).
- Known hypersensitivity to taurolidine, heparin or the citrate excipient (components of DefenCath), or pork products.
WARNINGS AND PRECAUTIONS
- Heparin-Induced Thrombocytopenia (HIT): HIT was reported in patients using heparin, a component of DefenCath, as a catheter lock solution. If HIT occurs, discontinue DefenCath and institute appropriate supportive measures.
- Drug Hypersensitivity: Drug hypersensitivity reactions have been reported in patients using heparin, a component of DefenCath, as a catheter lock solution. If a hypersensitivity reaction occurs, discontinue DefenCath and institute appropriate supportive measures.
ADVERSE REACTIONS
The most frequently reported adverse reactions occurring in ≥2% of patients using DefenCath as a CLS were hemodialysis catheter malfunction, hemorrhage/bleeding, nausea, vomiting, dizziness, musculoskeletal chest pain, and thrombocytopenia.
Indications and Usage
LIMITED POPULATION: DefenCath® is indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis (HD) through a central venous catheter (CVC). This drug is indicated for use in a limited and specific population of patients.
Limitations of Use
The safety and effectiveness of DefenCath have not been established for use in populations other than adult patients with kidney failure receiving chronic HD through a CVC.
Please see the full Prescribing Information.